In a landmark moment for medical innovation, OrganOx, a trailblazer in organ preservation technology, has secured a staggering $142 million in equity financing to propel its mission of transforming transplant care. Announced today, this funding round—led by HealthQuest Capital and supported by an elite roster of investors including BGF, Lauxera Capital Partners, Sofina, Soleus Capital, and Avidity Partners—underscores the global confidence in OrganOx’s pioneering metra platform. Already a cornerstone in over 5,000 liver transplants across the U.S., Europe, Canada, and Australia, this technology is rewriting the rules of organ viability and surgical precision.
At the heart of OrganOx’s success is its metra system, a marvel of modern engineering that keeps donor livers thriving outside the body for up to 24 hours. Unlike traditional cold storage, which merely slows decay, metra’s normothermic machine perfusion mimics the human body’s environment—circulating oxygen-rich blood at near-body temperature to sustain the organ’s metabolism. This not only grants transplant teams unprecedented flexibility in scheduling complex surgeries but also allows surgeons to evaluate the liver’s performance before implantation. Studies reveal a stunning outcome: metra slashes the discard rate of donor livers by 50%, breathing new hope into patients awaiting life-saving transplants.
The company’s ambition doesn’t stop at livers. OrganOx is now venturing into kidney preservation, with clinical trials slated to begin in the U.S., signaling its intent to broaden its impact across the transplant landscape. Yet, perhaps the most groundbreaking stride lies in its collaboration with eGenesis, a biotech innovator specializing in xenotransplantation. Together, they’ve harnessed metra to sustain genetically modified pig livers, successfully circulating human blood through these organs in a study last year using a brain-dead research donor. This partnership has since evolved into an exclusive co-development agreement, aiming to create an extracorporeal liver support system that could stabilize acute liver failure patients—potentially sparing them the need for a transplant altogether.
“This financing empowers us to expand our reach and deepen our research, addressing urgent needs in organ care,” said Oern R. Stuge, MD, MBA, Executive Chairman of OrganOx. “Organ disease remains a vast challenge, and we’re committed to improving outcomes alongside visionary partners like HealthQuest Capital.” Echoing this sentiment, Garheng Kong, MD, PhD, Founder and Managing Partner at HealthQuest Capital, added, “OrganOx’s technology is a triumph for patients, providers, and global health—a cost-effective solution that elevates care standards.”
Looking ahead, OrganOx and eGenesis are gearing up to seek FDA approval for a first-in-human trial in 2025, blending metra with engineered porcine livers to tackle acute liver failure. This fusion of cutting-edge perfusion and genetic ingenuity could redefine emergency care, offering a lifeline to thousands worldwide.
Editorial Opinion: A Beacon of Hope in Transplant Innovation
The trajectory of OrganOx signals a seismic shift in the transplant industry, where scarcity and time constraints have long cast shadows over patient outcomes. By doubling the window of organ viability and halving discard rates, this company is not merely enhancing logistics—it’s amplifying the very essence of life-saving potential. Its foray into kidney transplants and xenotransplantation with eGenesis reflects a bold, forward-thinking ethos that could ease the crushing demand on donor lists, a challenge that claims countless lives annually. The global transplant market, already burgeoning, stands to gain a leader that marries technological prowess with compassionate impact.
Beyond the numbers, OrganOx’s work carries a profound societal ripple. Its ability to bridge human and animal-derived solutions via metra hints at a future where organ shortages become a relic of the past. The focus on acute liver failure—a condition with staggering mortality rates—underscores a commitment to urgent, unmet needs. With robust investor backing and a clear roadmap, OrganOx is steering the industry toward a horizon of accessibility and resilience, proving that innovation, when wielded with purpose, can heal more than just bodies—it can restore hope
If you need further assistance or have any corrections, please reach out to editor@thetimesmag.com.
